These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 38992654)

  • 41. T cells expressing CD26-specific chimeric antigen receptors exhibit extensive self-antigen-driven fratricide.
    Zhou S; Zhu X; Shen N; Li Q; Wang N; You Y; Zhong Z; Cheng F; Zou P; Zhu X
    Immunopharmacol Immunotoxicol; 2019 Aug; 41(4):490-496. PubMed ID: 31303072
    [No Abstract]   [Full Text] [Related]  

  • 42. High Cytotoxic Efficiency of Lentivirally and Alpharetrovirally Engineered CD19-Specific Chimeric Antigen Receptor Natural Killer Cells Against Acute Lymphoblastic Leukemia.
    Müller S; Bexte T; Gebel V; Kalensee F; Stolzenberg E; Hartmann J; Koehl U; Schambach A; Wels WS; Modlich U; Ullrich E
    Front Immunol; 2019; 10():3123. PubMed ID: 32117200
    [TBL] [Abstract][Full Text] [Related]  

  • 43. TIM3 expression by leukemic and non-leukemic myeloblasts.
    Roth CG; Garner K; Eyck ST; Boyiadzis M; Kane LP; Craig FE
    Cytometry B Clin Cytom; 2013 May; 84(3):167-72. PubMed ID: 23554257
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Preclinical Evaluation of B7-H3-specific Chimeric Antigen Receptor T Cells for the Treatment of Acute Myeloid Leukemia.
    Lichtman EI; Du H; Shou P; Song F; Suzuki K; Ahn S; Li G; Ferrone S; Su L; Savoldo B; Dotti G
    Clin Cancer Res; 2021 Jun; 27(11):3141-3153. PubMed ID: 33531429
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Cooperative CAR targeting to selectively eliminate AML and minimize escape.
    Haubner S; Mansilla-Soto J; Nataraj S; Kogel F; Chang Q; de Stanchina E; Lopez M; Ng MR; Fraser K; Subklewe M; Park JH; Wang X; Rivière I; Sadelain M
    Cancer Cell; 2023 Nov; 41(11):1871-1891.e6. PubMed ID: 37802054
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Challenges and Advances in Chimeric Antigen Receptor Therapy for Acute Myeloid Leukemia.
    Marvin-Peek J; Savani BN; Olalekan OO; Dholaria B
    Cancers (Basel); 2022 Jan; 14(3):. PubMed ID: 35158765
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Overcoming target epitope masking resistance that can occur on low-antigen-expresser AML blasts after IL-1RAP chimeric antigen receptor T cell therapy using the inducible caspase 9 suicide gene safety switch.
    Warda W; Da Rocha MN; Trad R; Haderbache R; Salma Y; Bouquet L; Roussel X; Nicod C; Deschamps M; Ferrand C
    Cancer Gene Ther; 2021 Dec; 28(12):1365-1375. PubMed ID: 33414517
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Novel CAR T therapy is a ray of hope in the treatment of seriously ill AML patients.
    Marofi F; Rahman HS; Al-Obaidi ZMJ; Jalil AT; Abdelbasset WK; Suksatan W; Dorofeev AE; Shomali N; Chartrand MS; Pathak Y; Hassanzadeh A; Baradaran B; Ahmadi M; Saeedi H; Tahmasebi S; Jarahian M
    Stem Cell Res Ther; 2021 Aug; 12(1):465. PubMed ID: 34412685
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Allogeneic FLT3 CAR T Cells with an Off-Switch Exhibit Potent Activity against AML and Can Be Depleted to Expedite Bone Marrow Recovery.
    Sommer C; Cheng HY; Nguyen D; Dettling D; Yeung YA; Sutton J; Hamze M; Valton J; Smith J; Djuretic I; Chaparro-Riggers J; Sasu BJ
    Mol Ther; 2020 Oct; 28(10):2237-2251. PubMed ID: 32592688
    [TBL] [Abstract][Full Text] [Related]  

  • 50. CAR-NK cells for acute myeloid leukemia immunotherapy: past, present and future.
    Zhang L; Meng Y; Yao H; Zhan R; Chen S; Miao W; Ma S; Xu X; Li Y; Yu M; Han Y; Su W; Han Z; Wang T; Song B; Wang P; Cai H; Yan J
    Am J Cancer Res; 2023; 13(11):5559-5576. PubMed ID: 38058830
    [TBL] [Abstract][Full Text] [Related]  

  • 51. In Vitro Pre-Clinical Validation of Suicide Gene Modified Anti-CD33 Redirected Chimeric Antigen Receptor T-Cells for Acute Myeloid Leukemia.
    Minagawa K; Jamil MO; Al-Obaidi M; Pereboeva L; Salzman D; Erba HP; Lamb LS; Bhatia R; Mineishi S; Di Stasi A
    PLoS One; 2016; 11(12):e0166891. PubMed ID: 27907031
    [TBL] [Abstract][Full Text] [Related]  

  • 52. CD33-Specific Chimeric Antigen Receptor T Cells with Different Co-Stimulators Showed Potent Anti-Leukemia Efficacy and Different Phenotype.
    Li S; Tao Z; Xu Y; Liu J; An N; Wang Y; Xing H; Tian Z; Tang K; Liao X; Rao Q; Wang M; Wang J
    Hum Gene Ther; 2018 May; 29(5):626-639. PubMed ID: 29409351
    [TBL] [Abstract][Full Text] [Related]  

  • 53. NK cell defects: implication in acute myeloid leukemia.
    D'Silva SZ; Singh M; Pinto AS
    Front Immunol; 2023; 14():1112059. PubMed ID: 37228595
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Biomarkers as targets for CAR-T/NK cell therapy in AML.
    Shao R; Li Z; Xin H; Jiang S; Zhu Y; Liu J; Huang R; Xu K; Shi X
    Biomark Res; 2023 Jun; 11(1):65. PubMed ID: 37330575
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Chimeric antigen receptor-engineered cytokine-induced killer cells overcome treatment resistance of pre-B-cell acute lymphoblastic leukemia and enhance survival.
    Oelsner S; Wagner J; Friede ME; Pfirrmann V; Genßler S; Rettinger E; Buchholz CJ; Pfeifer H; Schubert R; Ottmann OG; Ullrich E; Bader P; Wels WS
    Int J Cancer; 2016 Oct; 139(8):1799-809. PubMed ID: 27253354
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Continuously expanding CAR NK-92 cells display selective cytotoxicity against B-cell leukemia and lymphoma.
    Oelsner S; Friede ME; Zhang C; Wagner J; Badura S; Bader P; Ullrich E; Ottmann OG; Klingemann H; Tonn T; Wels WS
    Cytotherapy; 2017 Feb; 19(2):235-249. PubMed ID: 27887866
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Chimeric antigen receptor (CAR) modified T Cells in acute myeloid leukemia: limitations and expectations.
    Guijarro-Albaladejo B; Marrero-Cepeda C; Rodríguez-Arbolí E; Sierro-Martínez B; Pérez-Simón JA; García-Guerrero E
    Front Cell Dev Biol; 2024; 12():1376554. PubMed ID: 38694825
    [TBL] [Abstract][Full Text] [Related]  

  • 58. CD38-directed CAR-T cell therapy: a novel immunotherapy strategy for relapsed acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation.
    Cui Q; Qian C; Xu N; Kang L; Dai H; Cui W; Song B; Yin J; Li Z; Zhu X; Qu C; Liu T; Shen W; Zhu M; Yu L; Wu D; Tang X
    J Hematol Oncol; 2021 May; 14(1):82. PubMed ID: 34034795
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A Bump in the Road: How the Hostile AML Microenvironment Affects CAR T Cell Therapy.
    Epperly R; Gottschalk S; Velasquez MP
    Front Oncol; 2020; 10():262. PubMed ID: 32185132
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Precision immunotherapy for cholangiocarcinoma: Pioneering the use of human-derived anti-cMET single chain variable fragment in anti-cMET chimeric antigen receptor (CAR) NK cells.
    Chiawpanit C; Wathikthinnakorn M; Sawasdee N; Phanthaphol N; Sujjitjoon J; Junking M; Yamabhai M; Panaampon J; Yenchitsomanus PT; Panya A
    Int Immunopharmacol; 2024 Jul; 136():112273. PubMed ID: 38810311
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.